DELAWARE
|
33-0824714
|
(State
of Incorporation)
|
(I.R.S.
Employer Identification No.)
|
|
|
|
|
8885
Rehco Road, San Diego, California
|
92121
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(FORMERLY
TASCO INTERNATIONAL, INC.)
|
(A
Development Stage Company)
|
Consolidated
Balance Sheets
|
ASSETS
|
|||||||
|
|||||||
|
|
As
of December 31, 2006
(unaudited)
|
|
As
of September 30, 2006
|
|||
CURRENT
ASSETS
|
|||||||
Cash
|
$ |
14,991
|
$ |
22,641
|
|||
Receivable
|
74
|
||||||
Pre-paid Expenses
|
-
|
20,207
|
|||||
|
|||||||
Total Current Assets
|
15,065
|
42,848
|
|||||
PROPERTY
& EQUIPMENT
|
365,070
|
340,557
|
|||||
GOODWILL
|
-
|
||||||
Intangible
Assets/Technology
|
-
|
||||||
Total
Other Assets
|
29,127
|
29,127
|
|||||
TOTAL
ASSETS
|
409,262
|
412,532
|
BIO-MATRIX
SCIENTIFIC GROUP, INC. AND SUBSIDIARY
|
(FORMERLY
TASCO INTERNATIONAL, INC.)
|
(A
Development Stage Company)
|
Consolidated
Balance Sheets
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
As
of December 31, 2006
(unaudited)
|
As
of September 30, 2006
|
|||||
|
|||||||
CURRENT
LIABILITIES
|
|||||||
Accounts payable
|
$ |
54,223
|
$ |
91,079
|
|||
Loans from former parent
|
-
|
1,195,196
|
|||||
Notes Payable
|
188,324
|
148,952
|
|||||
Accrued Payroll
|
4,000
|
-
|
|||||
Accrued Payroll Taxes
|
1,387
|
16,460
|
|||||
Accrued Interest
|
3,748
|
1,368
|
|||||
Accrued Expenses
|
3,863
|
-
|
|||||
Total Current Liabilities
|
255,545
|
1,453,055
|
|||||
LONG
TERM LIABILITIES
|
-
|
-
|
|||||
TOTAL
LIABILITIES
|
255,545
|
1,453,055
|
|||||
STOCKHOLDERS'
EQUITY
|
|||||||
Preferred
Stock ($.0001 par value authorized 20,000,000 shares authorized;
none issued and outstanding.)
|
|||||||
Common
Stock, ($.0001 par value authorized 80,000,000 shares authorized;
16,493,389 shares and 13,385,000
shares issued and outstanding as of December 31, 2006 and September 30, 2006) |
1,649
|
1339
|
|||||
Additional
paid in Capital
|
32,035,693
|
30,375,584
|
|||||
Deficit
accumulated during the development stage
|
(31,883,625
|
) |
(31,417,446
|
) | |||
Total Stockholders' Equity (Deficit)
|
153,717
|
(1,040,523
|
) | ||||
|
|||||||
TOTALLIABILITIES
& STOCKHOLDERS' EQUITY
|
$ |
409,262
|
$ |
412,532
|
BIO-MATRIX
SCIENTIFIC GROUP, INC. AND SUBSIDIARY
|
|||||||||
(FORMERLY
TASCO INTERNATIONAL, INC.)
|
|||||||||
(A
Development Stage Company)
|
|||||||||
Consolidated
Statements of Operations
(unaudited)
|
Inception
|
||||||||||
(October
6, 1998)
|
||||||||||
3
Months Ended
|
3
Months Ended
|
through
|
||||||||
Dec
31,
|
Dec
31,
|
Dec
31,
|
||||||||
2006
|
2005
|
2006
|
||||||||
(unaudited)
|
(unaudited)
|
(unaudited)
|
||||||||
REVENUES
|
||||||||||
Sales
|
$
|
-
|
$
|
-
|
$
|
1,000
|
||||
Total
Revenues
|
-
|
-
|
1,000
|
|||||||
COSTS
AND EXPENSES
|
||||||||||
Research
and Development
|
108,489
|
136,164
|
||||||||
General
and administrative
|
224,673
|
250
|
1,051,368
|
|||||||
Depreciation
and amortization
|
333
|
-
|
666
|
|||||||
Consulting
and professional fees
|
125,840
|
-
|
916,475
|
|||||||
Impairment
of goodwill & intangibles
|
-
|
29,777,222
|
||||||||
Total
Costs and Expenses
|
459,335
|
250
|
31,881,895
|
|||||||
OPERATING
LOSS
|
(459,335
|
)
|
(250
|
)
|
(31,880,395
|
)
|
||||
OTHER
INCOME & (EXPENSES)
|
||||||||||
Interest
Expense
|
(6,844
|
)
|
-
|
(8,212
|
)
|
|||||
Interest
Income
|
-
|
11
|
39
|
|||||||
Other
income
|
-
|
-
|
5,443
|
|||||||
Total
Other Income & (Expenses)
|
(6,844
|
)
|
11
|
(2,730
|
)
|
|||||
NET
INCOME (LOSS)
|
$
|
(466,179
|
)
|
$
|
(239
|
)
|
$
|
(31,883,625
|
)
|
|
BASIC
AND DILUTED EARNINGS (LOSS) PER SHARE
|
||||||||||
BASIC
AND DILUTED EARNINGS (LOSS) PER SHARE
|
$
|
(0.03
|
)
|
$
|
(0.00
|
)
|
$
|
-
|
||
WEIGHTED
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
|
15,275,294
|
12,780,000
|
-
|
BIO-MATRIX
SCIENTIFIC GROUP, INC. AND SUBSIDIARY
|
|
(FORMERLY
TASCO INTERNATIONAL, INC.)
|
|
(A
Development Stage Company)
|
|
Consolidated
Statements of Changes in Stockholders' Equity
(Deficit)
|
|
From
October 6, 1998 (inception) through December 31,
2006
|
|
(unaudited)
|
|
Common
|
Additional
Paid-in
|
Retained
|
|
||||||||||||
|
Shares
|
Amount
|
Capital
|
Earnings
|
Total
|
|||||||||||
Stock
issued for cash October 6, 1998
|
1,000,000
|
100
|
(90
|
)
|
10
|
|||||||||||
Stock
issued for cash October 9, 1998
|
1,300,000
|
130
|
1,170
|
1,300
|
||||||||||||
Stock
issued for cash October 9, 1998
|
190,000
|
19
|
171
|
190
|
||||||||||||
Stock
issued for cash April 1, 1999
|
290,000
|
29
|
261
|
290
|
||||||||||||
Net
Loss October 6,1998 (inception through September 30, 1999)
|
(295
|
)
|
(295
|
)
|
||||||||||||
Balance
September 30, 1999
|
2,780,000
|
278
|
1,512
|
(295
|
)
|
1,495
|
||||||||||
Stock
issued for cash October 19, 1999
|
10,000,000
|
1,000
|
9,000
|
10,000
|
||||||||||||
Net
Loss October 1,1999 through September 30, 2000
|
(367
|
)
|
(367
|
)
|
||||||||||||
Balance
September 30, 2000
|
12,780,000
|
1,278
|
10,512
|
(662
|
)
|
11,128
|
||||||||||
Net
Loss October 1, 2000 through September 30, 2001
|
(11,028
|
)
|
(11,028
|
)
|
||||||||||||
Balance
September 30, 2001
|
12,780,000
|
1,278
|
10,512
|
(11,690
|
)
|
100
|
||||||||||
Net
Loss October 1, 2001
|
||||||||||||||||
through
September 30, 2002
|
(4,257
|
)
|
(4,257
|
)
|
||||||||||||
Balance
September 30, 2002
|
12,780,000
|
1,278
|
10,512
|
(15,947
|
)
|
(4,157
|
)
|
|||||||||
Net
Loss October 1, 2002 through September 30, 2003
|
(4,328
|
)
|
(4,328
|
)
|
||||||||||||
Balance
September 30, 2003
|
12,780,000
|
1,278
|
10,512
|
(20,275
|
)
|
(8,485
|
)
|
|||||||||
Contributed
Capital
|
12,362
|
12,362
|
||||||||||||||
Net
Loss October 1, 2003 through September 30, 2004
|
(7,974
|
)
|
(7,974
|
)
|
||||||||||||
Balance
September 30, 2004
|
12,780,000
|
1,278
|
22,874
|
(28,249
|
)
|
(4,097
|
)
|
|||||||||
Contributed
Capital
|
9,021
|
9,021
|
||||||||||||||
Net
Loss October 1, 2004 through September 30, 2005
|
(6,667
|
)
|
(6,667
|
)
|
||||||||||||
Balance
September 30, 2005
|
12,780,000
|
1,278
|
31,895
|
(34,916
|
)
|
(1,743
|
)
|
|||||||||
Stock
Cancelled June 13, 2006
|
(10,000,000
|
)
|
(1,000
|
)
|
(1,000
|
)
|
||||||||||
Stock
issued June 13, 2006
|
10,000,000
|
1,000
|
28,999,000
|
29,000,000
|
||||||||||||
Stock
issued for services
|
305,000
|
31
|
759,719
|
759,750
|
||||||||||||
Stock
issued for Compensation
|
300,000
|
30
|
584,970
|
585,000
|
||||||||||||
Net
Loss October 1, 2005 through September 30, 2006
|
(31,382,530
|
)
|
(31,382,530
|
)
|
||||||||||||
Balance
September 30, 2006
|
13,385,000
|
1,339
|
30,375,584
|
(31,417,446
|
)
|
(1,040,523
|
)
|
|||||||||
Stock
issued for services
|
100,184
|
10
|
112,524
|
112,534
|
||||||||||||
Stock
issued for Compensation
|
153,700
|
15
|
101,465
|
101,480
|
||||||||||||
Stock
issued in exchange for canceling debt
|
2,854,505
|
284
|
1,446,120
|
1,446,404
|
||||||||||||
Net
Loss October 1, 2006 through December 31, 2006
|
(466,179
|
)
|
(466,179
|
)
|
||||||||||||
Balance
December 30, 2006
|
16,493,389
|
1,649
|
32,035,693
|
(31,883,625
|
)
|
157,717
|
BIO-MATRIX
SCIENTIFIC GROUP, INC. AND SUBSIDIARY
(FORMERLY
TASCO INTERNATIONAL, INC.)
(A
Development Stage Company)
Consolidated
Statements of Cash Flows
(unaudited)
|
3
Months Ended
|
3
Months Ended
|
October
6, 1998
(inception)
through
|
||||||||
December
31,
|
December
31,
|
December
31,
|
||||||||
2006
|
2005
|
2006
|
||||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||||
Net
(loss)
|
$ |
(466,179
|
) | $ |
(239
|
) | $ |
(31,883,625
|
) | |
Adjustments
to reconcile net loss to net cash (used in) provided by operating
activities:
|
||||||||||
Impairment
of goodwill and intangible asset
|
-
|
29,777,222
|
||||||||
Depreciation
expense
|
333
|
-
|
666
|
|||||||
Stock
issued for compensation
|
101,480
|
-
|
686,480
|
|||||||
Stock
issued for services
|
112,534
|
-
|
872,284
|
|||||||
Cancellation
of Debt
|
-
|
(5,443
|
) | |||||||
Stock
issued to cancel debt plus accrued interest
|
251,209
|
251,209
|
||||||||
Changes
in operating assets and liabilities:
|
||||||||||
(Increase)
decrease in receivables
|
(74
|
) |
(74
|
) | ||||||
(Increase)
decrease in prepaid expenses
|
20,207
|
-
|
||||||||
(Increase)
decrease in organizational costs
|
-
|
-
|
||||||||
Increase
(Decrease) in Accounts Payable
|
(36,856
|
) |
-
|
54,223
|
||||||
Increase
(Decrease) in Accrued Expenses
|
(4,830
|
) |
-
|
12,998
|
||||||
(Increase)
Decrease in Deposits
|
-
|
(29,127
|
) | |||||||
Net
Cash Provided by (Used in) Operating
Activities
|
(22,176
|
) |
(239
|
) |
(263,187
|
) | ||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||||
Purchases
of fixed assets
|
(24,846
|
) |
-
|
(365,736
|
) | |||||
Purchases
of Intangible assets
|
-
|
(29,777,222
|
) | |||||||
Net
Cash Provided by (Used in) Investing
Activities
|
(24,846
|
) |
-
|
(30,142,958
|
) | |||||
CASH
FLOWS FROM FINANCING ACTIVITIES
|
||||||||||
Common
stock issued for cash
|
-
|
1,278
|
||||||||
Additional
paid in Capital
|
-
|
-
|
29,036,338
|
|||||||
Principal
borrowings on notes
|
39,372
|
-
|
188,324
|
|||||||
Net
borrowings from related parties
|
3,500
|
1,195,196
|
||||||||
Net
Cash Provided by (Used in) Financing
Activities
|
39,372
|
3,500
|
30,421,136
|
|||||||
Net
Increase (Decrease) in Cash
|
(7,650
|
) |
3,261
|
14,991
|
||||||
Cash
at Beginning of Year
|
22,641
|
-
|
-
|
|||||||
Cash
at End of Period
|
$ |
14,991
|
$ |
-
|
$ |
(14,991
|
) | |||
Supplemental
Cash Flow Disclosures:
|
||||||||||
Cash
paid during period for interest
|
$ |
-
|
$ |
-
|
$ |
-
|
||||
Cash
paid during period for taxes
|
$ | $ | $ | |||||||
Non
cash disclosure items:
|
-
|
|||||||||
Stock
issued to cancel debt
|
1,195,195
|
|
2006
|
|||||
Acquisition
cost:
|
|
|
||||
Production
Equipment
|
|
|
US$
|
93,314
|
||
Production
Cleanroom
|
|
78,264
|
||||
Leasehold
improvement
|
|
188,981
|
||||
Office
equipment
|
|
3,057
|
||||
Computer
|
|
2,120
|
||||
Subtotal
|
|
365,736
|
||||
Less
accumulated depreciation
|
|
(666
|
)
|
|||
Total
|
|
|
US$
|
365,070
|
|
|
|
As
of December 31, 2006
|
|
|
|
|
|
|
Deferred
tax assets:
|
|
|
|
|
Net
operating tax carry forwards
|
|
$
|
10,840,433
|
|
Other
|
|
|
0
|
|
|
|
|
|
|
Gross
deferred tax assets
|
|
|
10,840,433
|
|
Valuation
allowance
|
|
|
(10,840,433
|
)
|
|
|
|
|
|
Net
deferred tax assets
|
|
$
|
0
|
|
1998
Net Operating Loss
|
|
$
|
(295)
|
|
1999
Net Operating Loss
|
|
|
(367)
|
|
2000
Net Operating Loss
|
|
|
(11,028)
|
|
2001
Net Operating Loss
|
|
|
(4,257)
|
|
2002
Net Operating Loss
|
|
|
(4,328)
|
|
2003
Net Operating Loss
|
|
|
(7,974)
|
|
2004
Net Operating Loss
|
|
|
(6,667)
|
|
2005
Net Operating Loss
|
|
|
(31,382,530)
|
|
Three
Months Ended December 31, 2006 Net Operating Loss
|
|
|
(466,179)
|
|
Net
Operating Loss
|
|
$
|
(31,883,625)
|
2006
|
$
227,739
|
||
2007
|
$
234,562
|
||
2008
|
$
241,611
|
||
2009
|
$
248,864
|
||
2010
|
$
234,377
|
|
Number
of
|
|
|
|
|
Shares
|
|
As
of December 31, 2006:
|
|
|
|
|
|
|
|
Granted
|
|
858,884*
|
|
|
|
|
|
Remaining
shares available for issuance under the Plan as of December 31,
2006
|
|
641,116
|
|
31.1
|
Certification
of Chief Executive Officer
|
|
|
31.2
|
Certification
of Acting Chief Financial Officer
|
|
|
32.1
|
Certification
of Chief Executive Officer under Section 906 of the Sarbanes-Oxley
Act of
2002.
|
|
|
32.2
|
Certification
of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley
Act of 2002.
|
|
|
Bio
Matrix Scientific Group, Inc,.
|
|
|
a
Delaware corporation
|
By:
|
/s/
David R. Koos
|
David
R. Koos
|
|
|
Chief
Executive Officer
|
|
Date:
February 14, 2007
|